CDEK
← All drugs Report issue

cefuroxime

Trade name: zinacef

Small moleculeapproved

Approved

Oct 19, 1983

Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic. Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefuroxime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infection: Enterobacter spp., Escherichia coli, Klebsiella spp., Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Cefuroxime is indicated for the treatment of patients with septicemia, meningitis, gonorrhea, lower respiratory tract, urinary tract, skin and skin-structure, bone and joint infections caused by susceptible strains of the designated organisms. — NCATS

Clinical trial activity

67 trials · 87 clinical orgs · 25 marketing orgs

Phase 1
11
Phase 2
11
Phase 3
6
Phase 4
24

Earliest trial started Apr 1, 1994 (NCT00530400)

Timeline

1980s

  1. Oct 19, 1983

    Teligent Pharmaceuticals — Earliest FDA Approval

  2. Oct 19, 1983

    Pharmaceutical Associates — Marketing Organization

  3. Oct 19, 1983

    Teligent Pharmaceuticals — NDA Secondary Org

  4. Oct 19, 1983

    Teligent Pharmaceuticals — NDA Organization

  5. Oct 19, 1983

    Pharmaceutical Associates — NDA Secondary Org

  6. Jan 10, 1986

    ACS Dobfar — Marketing Organization

  7. Jan 10, 1986

    Eli Lilly — Marketing Organization

  8. Dec 28, 1987

    GlaxoSmithKline — NDA Secondary Org

1990s

  1. Feb 26, 1993

    Watson Pharmaceuticals — Marketing Organization

  2. Apr 16, 1998

    Teva — Marketing Organization

  3. Sep 28, 1998

    Fresenius — Marketing Organization

  4. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Feb 21, 2001

    B. Braun — NDA Secondary Org

  2. Feb 15, 2002

    Ranbaxy — Marketing Organization

  3. Oct 2, 2002

    Apotex — Marketing Organization

  4. Jan 1, 2003

    Teva — Earliest Phase 1 Sponsor(trial)

  5. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  6. Apr 25, 2003

    Sun Pharmaceuticals — Marketing Organization

  7. Jul 25, 2003

    Lupin — Marketing Organization

  8. Oct 28, 2003

    Fosun — Marketing Organization

  9. Jan 9, 2004

    Hikma — Marketing Organization

  10. Oct 18, 2004

    Ani Pharmaceuticals — Marketing Organization

  11. Jul 29, 2005

    Atlantide Pharmaceuticals — Marketing Organization

  12. Jul 29, 2005

    Wockhardt — Marketing Organization

  13. Jul 29, 2005

    Chartwell Pharmaceuticals — Marketing Organization

  14. Mar 29, 2006

    Aurobindo Pharma — Marketing Organization

  15. Feb 15, 2008

    Orchid Pharma — Marketing Organization

  16. Feb 15, 2008

    ANDA Repository — Marketing Organization

  17. Oct 15, 2008

    Hospira — Marketing Organization

  18. Dec 30, 2009

    Samson Medical — Marketing Organization

2010s

  1. Jun 7, 2010

    Alkem Labs Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedOct 19, 1983

Chemistry & pharmacology

Loading structure…

SMILES

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1
Mol. weight
424.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 640/359
  • (6r,7r)-3-[(carbamoyloxy)methyl]-7-{[(2z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6r,7r)-3-[(carbamoyloxy)methyl]-7-{[(2z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • acetoxyethylcefuroxime
  • altacef
  • biofuroxim
  • britacef
  • cci 15641
  • cci-15641
  • cci-15641
  • cci-15641
  • cefaloxime
  • cefasyn
  • cefazine
  • ceftin
  • ceftin
  • ceftin
  • ceftin
  • cefuoxim
  • cefurax
  • cefuroxim
  • cefuroxim
  • cefuroxim
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime
  • cefuroxime 1-acetoxyethyl ester
  • cefuroxime acid
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime axetil
  • cefuroxime pivoxetil
  • cefuroxime pivoxetil
  • cefuroxime pivoxetil
  • cefuroxime pivoxetil
  • cefuroxime pivoxetil
  • cefuroxime sodium
  • cefuroxime sodium
  • cefuroxime sodium
  • cefuroxime sodium
  • cefuroxime sodium salt
  • cefuroximine
  • cefuroximine
  • cefuroximo
  • cefuroximo
  • cefuroximum
  • cefuroximum
  • cephuroxime
  • cephuroxime
  • cephuroxime
  • kefurox
  • kefurox
  • oraxim
  • zinacef
  • zinacef
  • zinacef
  • zinacef danmark
  • zinacef danmark
  • zinnat
  • zinnat
  • zinnat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06351891Phase 4Apr 30, 2024Shandong University
NCT06255366Phase 4Mar 28, 2024Chengdu University of Traditional Chinese Medicines
NCT05750966N/AJul 19, 2023University of Amsterdam, ZonMw: The Netherlands Organisation for Health Research and Development
NCT05784311Phase 4Mar 6, 2023Leiden University
NCT05609240Phase 2Jan 1, 2023Aneurin Bevan University Health Board, University of Birmingham, University of Leeds
NCT05337566N/ASep 5, 2022Kuopio University Hospital, University of Helsinki, University of Oulu, University of Tampere, University of Turku
NCT05392634Phase 3Feb 2, 2022Government of Russia, The Foundation for Cancer Research Support (RakFond)
NCT05398081Phase 2Dec 1, 2021University of Ibadan
NCT04723472N/AOct 1, 2021Huazhong University of Science and Technology, ShanghaiDongfang Hospital
NCT04479657Early Phase 1 (Phase 1)Aug 31, 2020China Academy of Chinese Medical Sciences, Tsinghua University
NCT04378868Phase 4May 18, 2020University of Helsinki
NCT04161599Phase 4Feb 29, 2020Universidad Autonoma de Barcelona
NCT04212078Phase 1/Phase 2 (Phase 2)Jul 29, 2019National University of Malaysia, Santen Inc., UKM Medical Centre
NCT04009772Phase 2/Phase 3 (Phase 3)Jul 1, 2019Assiut University
NCT05577273N/AAug 14, 2018Technion University
NCT03716804Phase 4Jun 6, 2018Bangladesh Medical University
NCT04303390Phase 4Feb 6, 2018Saud Al Babtain Cardiac Center
NCT03221504N/AJan 1, 2018Medical University of Warsaw
NCT03108690Phase 4May 1, 2017University of Copenhagen
NCT03141476Phase 4Mar 1, 2017University of Hamburg
Showing 20 of 67 trials
Page 1 / 4

Organizations

Research & Development (87)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of CopenhagenAcademic/Hospital5222001
MDS PharmaFor profit4012004
SandozFor profit4412004
TevaFor profit4412003
University of LjubljanaAcademic/Hospital3322006
Benazir Bhutto Hospital, RawalpindiAcademic/Hospital2212013
Gateway Medical ResearchFor profit2012003
PRACSFor profit2012004
Santen Inc.For profit2022003
Universidad Autonoma de BarcelonaAcademic/Hospital2212015
University of GenevaAcademic/Hospital2011994
University of HelsinkiAcademic/Hospital2222020
University of LeedsAcademic/Hospital2212015
University of Southern DenmarkAcademic/Hospital2212014
Aarhus UniversityAcademic/Hospital1112001
Aase and Ejnar Danielsens FoundationAcademic/Hospital1012014
Adams LaboratoriesFor profit1011999
Aneurin Bevan University Health BoardAcademic/Hospital1012023
Assiut UniversityAcademic/Hospital1112019
Bangladesh Medical UniversityAcademic/Hospital1112018
87 organizations
Page 1 / 5

Marketing (31)

OrganizationOrg typeRelationshipDate
ACS DobfarFor profitMKTGJan 10, 1986
ACS DobfarFor profitSYNMay 30, 1997
ANDA RepositoryFor profitMKTGFeb 15, 2008
Alkem Labs LtdFor profitMKTGJun 7, 2010
Ani PharmaceuticalsFor profitMKTGOct 18, 2004
Ani PharmaceuticalsFor profitSYNOct 18, 2004
ApotexFor profitMKTGOct 2, 2002
Atlantide PharmaceuticalsFor profitMKTGJul 29, 2005
Aurobindo PharmaFor profitMKTGMar 29, 2006
Aurobindo PharmaFor profitSYNMar 29, 2006
B. BraunFor profitNDA2Feb 21, 2001
Chartwell PharmaceuticalsFor profitMKTGJul 29, 2005
Eli LillyFor profitMKTGJan 10, 1986
FosunFor profitMKTGOct 28, 2003
FreseniusFor profitMKTGSep 28, 1998
GlaxoSmithKlineFor profitNDA2Dec 28, 1987
HikmaFor profitMKTGJan 9, 2004
HikmaFor profitSYNJan 9, 2004
HospiraFor profitMKTGOct 15, 2008
LupinFor profitMKTGJul 25, 2003
Orchid PharmaFor profitMKTGFeb 15, 2008
Pharmaceutical AssociatesFor profitMKTGOct 19, 1983
Pharmaceutical AssociatesFor profitNDA2Oct 19, 1983
RanbaxyFor profitMKTGFeb 15, 2002
Samson MedicalFor profitMKTGDec 30, 2009
Sun PharmaceuticalsFor profitMKTGApr 25, 2003
Teligent PharmaceuticalsFor profitNDA2Oct 19, 1983
Teligent PharmaceuticalsFor profitNDAOct 19, 1983
TevaFor profitMKTGApr 16, 1998
Watson PharmaceuticalsFor profitMKTGFeb 26, 1993
WockhardtFor profitMKTGJul 29, 2005